Cel-Sci (NYSE:CVM) said today that it inked an agreement with institutional investors for a $3.5 million registered direct offering. The company said it plans to offer 1.75 million shares of common stock at $2.00 apiece. In a private placement, Cel-Sci will issue warrants to buy up to 1.75 million shares of common stock. For each share of stock purchased […]
Oncology
Sirtex swings to a loss after ‘challenging’ year
Shares in Australian cancer treatment developer Sirtex Medical (ASX:SRX) plunged more than 15% yesterday after the company posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54 million the year before. Sirtex has faced a barrage of obstacles this year, including a number of clinical trials that failed to meet primary endpoints. […]
Study: Annual mammograms would prevent the most deaths
(Reuters) – Yearly mammograms starting at age 40 would prevent the most deaths from breast cancer, U.S. researchers reported on Monday in a challenge to more conservative recommendations that take into account both the harms and the benefits of screening. The study, led by Dr. Elizabeth Arleo, a radiologist specializing in mammography at Weill Cornell […]
BTG helps fund immuno-oncology drug-device research programs
BTG (LON:BTG) and the Society of Interventional Oncology said today that it expanded its immuno-oncology/interventional oncology research grant program. The group launched a second round of funding, designed help evaluate minimally invasive, image-guided therapies that use the body’s own immune system to treat cancer. Get the full story at our sister site, Drug Delivery Business News.
Nanotech, immunotherapy combo vaccinates mouse against cancer
Researchers from Duke University combined an FDA-approved cancer immunotherapy with gold nanostars to boost the cancer-killing abilities of both therapies, according to a study published this week in Scientific Reports. The combination therapy cured two mice and vaccinated one against bladder cancer, the team reported. Get the full story at our sister site, Drug Delivery Business News.
Report: Olympus study of next-gen power morcellator draws criticism
Olympus (TYO:7733) is receiving criticism after moving forward with plans to revitalize its powered morcellator devices, with a new 140-patient trial planned, according to a Philadelphia Inquirer report. Power morcellators, which use a cutting tip to shred and remove uterine tissue, have been implicated in the spread of a lethal cancer that can masquerade undetected as […]
Cancer diagnostic detects unique mutations in small amount of blood
Researchers from Stanford University have developed a new diagnostic tool that can detect genetic mutations in small amounts of tumor-derived DNA circulating in a patient’s blood sample. The single color digital PCR assay needs a fraction of a tube of blood and can successfully detect three mutation-bearing molecules in a single reaction, according to the report published […]
7 medtech stories we missed this week: August 11, 2017
From Xtant Medical’s 510(k) extension to Varian Medical’s distribution deal, here are seven medtech stories we missed this week but thought were still worth a mention. 1. FDA extends Xtant Medical’s 510(k) for Calix C spinal implant Xtant Medical announced in an Aug. 9 press release that the FDA has cleared its product line extensions […]
Inovio tops Q2 sales estimate by $4m
Shares in Inovio Pharmaceuticals (NSDQ:INO) rose today after the pharmaceutical company beat expectations on Wall Street with its second quarter results. The Plymouth Meeting, Penn.-based company posted a net loss of -$9.5 million on sales of $20.4 million for the 3 months ended June 30, for bottom-line growth of 49% compared with the same period last year. Get the full […]
Varian Medical touts 1st commercial use of its HyperArc system
Varian Medical‘s (NYSE:VAR) said today that the 1st patient has been treated with its HyperArc high definition radiotherapy system at Negrar-Verona, Italy’s Sacro Cuore Don Calabria Cancer Care Center. The Palo Alto, Calif.-based company’s HyperArc system is designed around its TrueBeam and Edge treatment platform, and delivers more compact radiation doses to fully saturate a […]
Novocure wins Austrian reimbursement for Optune
Novocure (NSDQ:NVCR) said today it won reimbursement across Austria for its Optune tumor treating fields delivery system designed for treating newly diagnosed glioblastoma. The St. Helier, N.J.-based company said it inked a contract with the Federation of the Austrian Social Insurance Institutions to grant reimbursement across the country, and that all 18 Austrian insurance funds have […]